Objective: To determine whether adding REM sleep behavior disorder (RBD) to the dementia with Lewy bodies (DLB) diagnostic criteria improves classification accuracy of autopsy-confirmed DLB.
Methods: We followed 234 consecutive patients with dementia until autopsy with a mean of 4 annual visits. Clinical diagnoses included DLB, Alzheimer disease (AD), corticobasal syndrome, and frontotemporal dementia. Pathologic diagnoses used the 2005 DLB consensus criteria and included no/low likelihood DLB (non-DLB; n = 136) and intermediate/high likelihood DLB (DLB; n = 98). Regression modeling and sensitivity/specificity analyses were used to evaluate the diagnostic role of RBD.
Results: Each of the 3 core features increased the odds of autopsy-confirmed DLB up to 2-fold, and RBD increased the odds by 6-fold. When clinically probable DLB reflected dementia and 2 or more of the 3 core features, sensitivity was 85%, and specificity was 73%. When RBD was added and clinically probable DLB reflected 2 or more of 4 features, sensitivity improved to 88%. When dementia and RBD were also designated as probable DLB, sensitivity increased to 90% while specificity remained at 73%. The VH, parkinsonism, RBD model lowered sensitivity to 83%, but improved specificity to 85%.
Conclusions: Inclusion of RBD as a core clinical feature improves the diagnostic accuracy of autopsy-confirmed DLB.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3162640 | PMC |
http://dx.doi.org/10.1212/WNL.0b013e31822c9148 | DOI Listing |
Alzheimers Dement
December 2024
Department of Neurology, Mayo Clinic, Rochester, MN, USA.
Background: Many proposed clinical decision support systems (CDSS) require multiple disparate data elements as input, which makes implementation difficult, and furthermore have a black-box nature leading to low interpretability. Fluorodeoxyglucose Positron Emission Tomography (FDG-PET) is an established modality for the diagnosis of dementia, and a CDSS that uses only an FDG-PET image to produce a reliable and understandable result would ease both of these challenges to clinical application.
Method: A deep variational autoencoder (VAE) was used to extract a latent representation of each image through prior training from FDG-PET brain images (n=2000).
Alzheimers Dement
December 2024
Division of Clinical Geriatrics, Center for Alzheimer Research, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Stockholm, Sweden.
Background: Patterns of regional atrophy and hypometabolism have been observed in dementia with Lewy bodies (DLB). However, determinants of regional vulnerability to structural and functional neurodegeneration remain largely unexplored. First, we investigated the association between regional gene expression and grey matter volumes in probable DLB patients.
View Article and Find Full Text PDFBackground: Dementia with Lewy bodies (DLB) frequently co-occurs with Alzheimer's disease (AD) pathologies, exacerbating disease progression. Biophysical models of diffusion imaging data, such as Neurite Orientation Dispersion and Density Imaging (NODDI), may reveal novel insights into the neurobiological substrates of AD on cortical and white matter microstructural injury.
Method: A cohort of 57 DLB patients on the DLB spectrum (33 clinically probable DLB and 14 prodromal DLB) and 57 cognitively unimpaired (CU) controls underwent NODDI and PET imaging with [F]-Flortaucipir and [C]-PiB (Table 1).
Alzheimers Dement
December 2024
Leenaards Memory Center, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
Background: Cerebral amyloid angiopathy (CAA) has been reported in patients with dementia with Lewy bodies (DLB) and Alzheimer's disease (AD), with a similar prevalence from pathology studies. CAA typically affects posterior regions, but amyloid deposits have been observed in the striatum in patients with DLB and with hereditary CAA. Here, we postulated that CAA-related amyloid pathology results in a different spatial pattern of damage in DLB with respect to AD, and we tested this hypothesis in vivo, by characterizing gray matter imaging features in patients with DLB and AD with and without CAA (CAApos, CAAneg).
View Article and Find Full Text PDFBackground: This study set to determine if 123I-ioflupane SPECT striatal binding ratio (SBR) correlated with parkinsonian symptoms measured on Movement Disorder Society - Unified Parkinson's Disease Rating Scale Part III (UPDRS-III) in a dementia with Lewy bodies (DLB) cohort and if SBR measured at baseline could predict progression of parkinsonian symptoms over 2 years.
Methods: This is a retrospective cohort study using the U.S.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!